Glynase Tablet contains Glipizide 5mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby lowering blood glucose levels. Glynase is primarily prescribed as an adjunct to diet and exercise to improve glycemic control in adults with non-insulin-dependent diabetes. The onset of action typically occurs within 30 minutes, with peak effects observed between 1 to 3 hours post-administration, and a duration of action lasting up to 24 hours. Dosage should be individualized based on patient response and glycemic targets, with careful titration to minimize the risk of hypoglycemia. Contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Caution is advised in patients with hepatic or renal impairment, as well as in elderly individuals due to increased susceptibility to hypoglycemia. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Regular monitoring of blood glucose and HbA1c levels is essential to assess therapeutic efficacy and safety. Glynase should be used under medical supervision, with patient education on recognizing and managing hypoglycemia to optimize treatment outcomes.